| Schedule of Basic and Diluted Net Income (Loss) per Share Attributable to Common Stockholders |
Basic and diluted net income (loss) per share attributable to common stockholders is calculated as follows (in thousands, except share and per share amounts): | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | Nine Months Ended September 30, | | 2026 | | 2025 | 2026 | | 2025 | | Numerator: | | | | | | | | Net income (loss) | $ | 60,110 | | | $ | (64,469) | | $ | (72,478) | | | $ | (181,074) | | | Add: interest expense on convertible note | 752 | | — | — | | — | | Net income (loss) – diluted | $ | 60,862 | | | $ | (64,469) | | $ | (72,478) | | | $ | (181,074) | | | Denominator: | | | | | | | | Weighted-average shares of common stock outstanding – basic and diluted | 100,174,038 | | 68,016,817 | 78,885,912 | | 67,998,124 | | Dilutive effect of stock options, warrants and RSUs | 1,713,545 | | — | | — | | | — | | | Dilutive effect of Roche convertible note (if-converted) | 1,334,258 | | — | | — | | | — | | | Weighted-average shares of common stock outstanding – diluted | 103,221,841 | | | 68,016,817 | | 78,885,912 | | | 67,998,124 | | | Net income (loss) per share attributable to common stockholders – basic | $ | 0.60 | | | $ | (0.95) | | $ | (0.92) | | | $ | (2.66) | | | Net income (loss) per share attributable to common stockholders – diluted | $ | 0.58 | | | $ | (0.95) | | $ | (0.92) | | | $ | (2.66) | |
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share |
The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net income (loss) per share, as their effect is anti-dilutive:
| | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, 2026 | | Three Months Ended September 30, 2025 | | Nine Months Ended September 30, 2026 | | Nine Months Ended September 30, 2025 | | Options to purchase common stock | 3,997,960 | | 6,337,275 | | 8,256,236 | | 6,337,275 | | Restricted stock units issued and outstanding | 3,853,553 | | 4,263,933 | | 3,879,655 | | 4,263,933 | | Warrants to purchase common stock | — | | | 14,003 | | 14,003 | | 14,003 | | Convertible notes | 2,523,611 | | — | | | 7,814,384 | | — | | | Total | 10,375,124 | | 10,615,211 | | 19,964,278 | | 10,615,211 |
|